[go: up one dir, main page]

CL2009000393A1 - Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular. - Google Patents

Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.

Info

Publication number
CL2009000393A1
CL2009000393A1 CL2009000393A CL2009000393A CL2009000393A1 CL 2009000393 A1 CL2009000393 A1 CL 2009000393A1 CL 2009000393 A CL2009000393 A CL 2009000393A CL 2009000393 A CL2009000393 A CL 2009000393A CL 2009000393 A1 CL2009000393 A1 CL 2009000393A1
Authority
CL
Chile
Prior art keywords
agent
useful
treatment
cell proliferation
pharmaceutical composition
Prior art date
Application number
CL2009000393A
Other languages
English (en)
Inventor
Dinh Tuan Vo
Jr Frederic A Bourke
Original Assignee
Duke Univ Y Immunolight Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40985931&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000393(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duke Univ Y Immunolight Llc filed Critical Duke Univ Y Immunolight Llc
Publication of CL2009000393A1 publication Critical patent/CL2009000393A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0066—Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Composición farmacéutica que comprende a) un agente farmacéutico activable, b) un agente activo plasmónico; útil para el tratamiento de trastornos de proliferación celular.
CL2009000393A 2008-02-21 2009-02-20 Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular. CL2009000393A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3043708P 2008-02-21 2008-02-21

Publications (1)

Publication Number Publication Date
CL2009000393A1 true CL2009000393A1 (es) 2010-01-04

Family

ID=40985931

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000393A CL2009000393A1 (es) 2008-02-21 2009-02-20 Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.

Country Status (5)

Country Link
US (4) US8951561B2 (es)
AR (1) AR070461A1 (es)
CL (1) CL2009000393A1 (es)
TW (2) TWI458512B (es)
WO (1) WO2009105662A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8376013B2 (en) 2008-03-11 2013-02-19 Duke University Plasmonic assisted systems and methods for interior energy-activation from an exterior source
US9358292B2 (en) * 2007-04-08 2016-06-07 Immunolight, Llc Methods and systems for treating cell proliferation disorders
US9488916B2 (en) * 2007-04-08 2016-11-08 Immunolight, Llc. Interior energy-activation of photo-reactive species inside a medium or body
US8507785B2 (en) * 2007-11-06 2013-08-13 Pacific Integrated Energy, Inc. Photo induced enhanced field electron emission collector
TWI458512B (zh) * 2008-02-21 2014-11-01 Immunolight Llc 利用電漿子增強之光譜療法（ｐｅｐｓｔ）及激子－電漿增強之光療法〈epep〉治療細胞增生病症之組合物及產生自體疫苗之系統
US9907976B2 (en) * 2011-07-08 2018-03-06 Immunolight, Llc Phosphors and scintillators for light stimulation within a medium
CN102056625B (zh) * 2008-04-04 2015-11-25 免疫之光有限责任公司 用于原位光生物调节的非侵入性系统和方法
US8770203B2 (en) 2008-07-14 2014-07-08 Immunolight, Llc. Advanced methods and systems for treating cell proliferation disorders
EP2359162A1 (en) * 2008-11-21 2011-08-24 Siemens A/S Radiation detector with doped optical guides
WO2010120297A1 (en) * 2009-04-15 2010-10-21 Hewlett-Packard Development Company, L.P Nanowire sensor having a nanowire and electrically conductive film
AR076361A1 (es) * 2009-04-21 2011-06-08 Immunoligtht Llc Composicion farmaceutica. kit. metodos y sistemas de conversion ascendente de energia no invasivos para la fotobiomodulacion in-situ
KR101196667B1 (ko) * 2010-04-15 2012-11-02 포항공과대학교 산학협력단 피에이치 민감성 금속 나노 입자를 이용한 항암제 전달 시스템
US8703907B2 (en) 2010-05-05 2014-04-22 Prolynx Llc Controlled drug release from dendrimers
KR20130129886A (ko) 2010-06-08 2013-11-29 퍼시픽 인테그레이티드 에너지, 인크. 강화된 필드들 및 전자 방출을 갖는 광학 안테나들
US20120020885A1 (en) * 2010-07-26 2012-01-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware MHC-Less cells
US20130012754A1 (en) * 2011-07-07 2013-01-10 Empire Technology Development Llc Microwave induced photodynamic therapy
WO2013013245A2 (en) 2011-07-21 2013-01-24 The Regents Of The University Of California Catalytic delivery nanoubstrates (cdns) for highly efficient delivery of biomolecules
WO2013033513A1 (en) 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
WO2013082304A1 (en) * 2011-11-29 2013-06-06 The Regents Of The University Of California Photonic nanoantenna mediated gene circuit reconfiguration
WO2013151772A1 (en) * 2012-04-06 2013-10-10 The Regents Of The University Of California Geometry enhancement of nanoscale energy deposition by x-rays
BR112015006873A2 (pt) 2012-09-27 2017-07-04 Rhodia Operations processo para produzir nanoestruturas de prata e copolímero útil em tal processo
EP3003286B1 (en) * 2013-05-24 2022-04-27 Nanexa AB Method of preparing solid nanoparticles with inorganic coating and use thereof
US9329310B1 (en) * 2013-07-26 2016-05-03 The United States Of America As Represented By The Secretary Of The Army MultiLayered plexcitonic nanoparticles and methods of producing same for controlling plasmon-exciton distance
EP2857123A1 (en) * 2013-10-04 2015-04-08 Total Marketing Services Light absorber
EP2913672A1 (de) * 2014-02-27 2015-09-02 Yerzhan Ussembayev Plexzitone zur Verwendung bei der Kontrolle von Zellmembran-Ionenkanalaktivität
US10398663B2 (en) * 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US11534622B2 (en) * 2014-08-18 2022-12-27 Immunolight, Llc Non-invasive systems and methods for selective activation of photoreactive responses
US9937359B1 (en) 2015-02-19 2018-04-10 University Of South Florida Plasmonic stimulation of electrically excitable biological cells
AU2015200886A1 (en) * 2015-02-20 2016-09-08 Monash University Carbon-based surface plasmon source and applications thereof
WO2016196783A1 (en) * 2015-06-04 2016-12-08 The Regents Of The University Of California Combination of isolated individual enhancements of x-ray radiation effect by nanomaterials
PL412787A1 (pl) 2015-06-22 2017-01-02 Magdalena Król Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
EP3349736A4 (en) 2015-09-16 2019-10-16 La Jolla Nanomedical NANOPARTICLE SYSTEM FACED ON CELL ACTIVITY AND METHOD FOR PRODUCING THE NANOPARTICLE SYSTEM
WO2017127759A1 (en) * 2016-01-22 2017-07-27 The Regents Of The University Of California Formation and use of embedded solutions in nanoscale materials
KR102465104B1 (ko) * 2016-04-25 2022-11-10 이뮤노라이트, 엘엘씨 삽입 디바이스들 및 매질 내부에 방출 광의 생산을 위한 시스템들 및 이들의 사용 방법들
US10231664B2 (en) * 2016-05-26 2019-03-19 Raghav Ganesh Method and apparatus to predict, report, and prevent episodes of emotional and physical responses to physiological and environmental conditions
CN106168574B (zh) * 2016-07-15 2018-12-25 华东师范大学 一种基于核壳结构纳米颗粒强耦合对局域环境的探测方法
AU2017384425B2 (en) 2016-12-21 2023-08-31 Nanobiotix Nanoparticles for use for treating a neuronal disorder
CN108622987A (zh) * 2017-03-17 2018-10-09 周金华 一种稳定水中光子振动频率和细小化磁性流体性状的装置及方法
DE102017002645A1 (de) * 2017-03-17 2018-09-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Bestrahlung von Säugetierzellen mit Elektronenstrahlen und/oder Röntgenstrahlen
US11077475B2 (en) * 2017-05-23 2021-08-03 International Business Machines Corporation Neuro-chemical sensor with inhibition of fouling on nano-electrode
US11207409B2 (en) * 2017-05-31 2021-12-28 Immunolight, Llc X-RAY psoralen activated cancer therapy (X-PACT) with associated treatments
US11331019B2 (en) 2017-08-07 2022-05-17 The Research Foundation For The State University Of New York Nanoparticle sensor having a nanofibrous membrane scaffold
US10583282B2 (en) 2017-11-13 2020-03-10 International Business Machines Corporation Neuro-stem cell stimulation and growth enhancement with implantable nanodevice
CN111954519A (zh) 2017-12-06 2020-11-17 新南创新私人有限公司 用于药物递送的脂质体系统
CN108732005B (zh) * 2018-03-27 2021-01-01 安徽大学 一种区分8-羟基喹啉及其同分异构体4-羟基喹啉的方法
US10727431B2 (en) 2018-06-29 2020-07-28 International Business Machines Corporation Optoelectronic devices based on intrinsic plasmon-exciton polaritons
CA3131865A1 (en) * 2019-03-04 2020-09-10 Immunolight, Llc. Energy augment structures for use with energy emitters and collectors
TWI699524B (zh) * 2019-05-20 2020-07-21 國立清華大學 一種高增益表面拉曼散射裝置及其製造方法
CN111965156B (zh) * 2019-05-20 2023-10-13 万德辉 一种高增益表面拉曼散射装置及其制造方法
CN112625674B (zh) * 2019-09-24 2022-04-29 Tcl科技集团股份有限公司 复合材料和量子点发光二极管及其制备方法
CN113181873A (zh) * 2021-01-29 2021-07-30 辽宁科技大学 TiO2-Fe-炭黑-煤沥青基球形活性炭的制备方法
CN115046967B (zh) * 2022-02-22 2025-05-20 中国人民解放军战略支援部队航天工程大学 一种激子极化激元凝聚体涡旋产生和检测装置
CN114621760B (zh) * 2022-03-10 2023-05-05 中国人民解放军国防科技大学 一种表面等离激元协同增强的钙钛矿量子点及其制备方法
CN116589491B (zh) * 2023-05-12 2025-09-12 郑州大学 汞激活型sers纳米探针及其制备方法、应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111890A (en) 1977-12-19 1978-09-05 Sws Silicones Corporation Curable organopolysiloxane compositions containing titanium esters
US4675346A (en) 1983-06-20 1987-06-23 Loctite Corporation UV curable silicone rubber compositions
US4838852A (en) 1987-03-27 1989-06-13 Therakos, Inc. Active specific immune suppression
US5177073A (en) * 1988-09-30 1993-01-05 Baylor Research Institute Therapeutic compositions derived from photoactive compounds
US4979935A (en) 1989-02-21 1990-12-25 Quantex Corporation Method of photodynamic therapy employing electron trapping material
US5658722A (en) 1990-05-15 1997-08-19 New York Blood Center, Inc. Process for the sterilization of biological compositions using UVA1 irradiation
US5120649A (en) 1990-05-15 1992-06-09 New York Blood Center, Inc. Photodynamic inactivation of viruses in blood cell-containing compositions
US5118422A (en) 1990-07-24 1992-06-02 Photo-Catalytics, Inc. Photocatalytic treatment of water
FR2677030B1 (fr) 1991-05-27 1994-05-06 Chemoxal Sa Procede d'obtention de cyclodextrines ou autres composes susceptibles de former des clathrates avec un gaz.
ES2110002T3 (es) 1991-06-21 1998-02-01 Baxter Int Procedimiento de inactivacion de agentes patogenos en fluidos corporales.
US6204058B1 (en) 1992-02-07 2001-03-20 Vasogen Ireland Limited Treatment of autoimmune diseases
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US6669965B2 (en) 1992-02-07 2003-12-30 Vasogen Ireland Limited Method of treating atherosclerosis
US5807881A (en) 1992-05-27 1998-09-15 Quadra Logic Technologies, Inc. Method for selectively reducing activated leukocyte cell population
US5728590A (en) 1994-07-29 1998-03-17 Nanoprobes, Inc. Small organometallic probes
US6121425A (en) 1994-07-29 2000-09-19 Nanoprobes, Inc. Metal-lipid molecules
US5521289A (en) 1994-07-29 1996-05-28 Nanoprobes, Inc. Small organometallic probes
US6235508B1 (en) * 1995-06-07 2001-05-22 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
IT1275571B (it) 1995-07-19 1997-08-07 Consiglio Nazionale Ricerche Substrati fluorogenici suscettibili di fotoattivazione previa trasformazione per via enzimatica atti alla diagnosi ed alla terapia fotodinamica dei tumori
JP3689939B2 (ja) 1995-07-28 2005-08-31 豊田合成株式会社 光触媒装置
JPH09299937A (ja) 1996-05-09 1997-11-25 Daikin Ind Ltd 被処理体処理装置
JPH1010741A (ja) 1996-06-27 1998-01-16 Dow Corning Asia Kk 紫外線硬化性ポリシロキサン組成物およびこれを用いた硬化物パターンの製造方法
US5829448A (en) 1996-10-30 1998-11-03 Photogen, Inc. Method for improved selectivity in photo-activation of molecular agents
US6344272B1 (en) * 1997-03-12 2002-02-05 Wm. Marsh Rice University Metal nanoshells
US5957960A (en) 1997-05-05 1999-09-28 Light Sciences Limited Partnership Internal two photon excitation device for delivery of PDT to diffuse abnormal cells
US6071944A (en) 1997-11-12 2000-06-06 Bowling Green State University Method of treatment of pigmented cancer cells utilizing photodynamic therapy
US7267948B2 (en) 1997-11-26 2007-09-11 Ut-Battelle, Llc SERS diagnostic platforms, methods and systems microarrays, biosensors and biochips
US20030022170A1 (en) 1998-03-06 2003-01-30 Millenium Pharmaceuticals, Inc. Novel fibroblast growth factors and therapeutic and diagnostic uses therefor
WO1999062960A1 (en) 1998-06-01 1999-12-09 Loctite Corporation Flame-retardant uv curable silicone compositions
US6323253B1 (en) 1998-06-01 2001-11-27 Loctite Corporation Flame-retardant UV and UV/moisture curable silicone compositions
WO2000006244A2 (en) 1998-07-30 2000-02-10 Hainfeld James F Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy
US7045124B1 (en) 1999-01-12 2006-05-16 Vasogen Irelend Limited Pre-conditioning against cell death
WO2001005001A1 (en) 1999-07-12 2001-01-18 Massachusetts Institute Of Technology Resonant microcavities
US20020127224A1 (en) * 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
US6670113B2 (en) 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
US7364872B1 (en) 2001-03-30 2008-04-29 Nanoprobes Test methods using enzymatic deposition and alteration of metals
US7008559B2 (en) 2001-06-06 2006-03-07 Nomadics, Inc. Manganese doped upconversion luminescence nanoparticles
EP1465699A4 (en) 2001-12-12 2006-05-24 Leon J Lewandowski AUTOIMMUNE STIMULATION BY PHOTOPHORESIS
US20070189359A1 (en) 2002-06-12 2007-08-16 Wei Chen Nanoparticle thermometry and pressure sensors
EP1670512A2 (en) 2003-09-23 2006-06-21 Light Sciences Corporation Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted pdt agents
US20070274909A1 (en) 2003-12-17 2007-11-29 Koninklijke Philips Electronic, N.V. Radiation Therapy and Medical Imaging Using Uv Emitting Nanoparticles
US7294656B2 (en) 2004-01-09 2007-11-13 Bayer Materialscience Llc UV curable coating composition
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
GB0415663D0 (en) 2004-07-13 2004-08-18 Psimei Pharmaceuticals Plc Compound
US20060067889A1 (en) 2004-09-27 2006-03-30 Light Sciences Corporation Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents
WO2006037081A2 (en) 2004-09-28 2006-04-06 The Regents Of The University Of California Nanoparticle radiosensitizers
FR2877571B1 (fr) 2004-11-05 2007-04-13 Nanobiotix Sarl Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations
US7397043B2 (en) 2005-01-26 2008-07-08 Nomadics, Inc. Standoff optical detection platform based on surface plasmon-coupled emission
US20070218049A1 (en) * 2006-02-02 2007-09-20 Wei Chen Nanoparticle based photodynamic therapy and methods of making and using same
US7538329B2 (en) 2005-02-02 2009-05-26 Nomadics, Inc. Energy-transfer nanocomposite materials and methods of making and using same
JP2007108512A (ja) 2005-10-14 2007-04-26 Fujifilm Corp 反射防止フィルム、並びにそれを用いた偏光板及び画像表示装置
EP1779891A1 (en) 2005-10-28 2007-05-02 Abdula Kurkayev Method of activating a photosensitizer
WO2007108512A1 (ja) 2006-03-22 2007-09-27 T.N.G. Technologies Co., Ltd. 金属コーティング材の製造方法及び金属コーティング材
US20070243137A1 (en) 2006-04-18 2007-10-18 Nanoprobes, Inc. Cell and sub-cell methods for imaging and therapy
US20090191128A1 (en) 2006-07-10 2009-07-30 Koninklijke Philips Electronics N.V. Core-shell nanoparticles for thearapy and imaging purposes
US8328785B2 (en) 2006-09-18 2012-12-11 The University Of Houston System Use of nanoparticles in the photodynamic treatment of tumors
US7906147B2 (en) 2006-10-12 2011-03-15 Nanoprobes, Inc. Functional associative coatings for nanoparticles
US9358292B2 (en) 2007-04-08 2016-06-07 Immunolight, Llc Methods and systems for treating cell proliferation disorders
US20090104212A1 (en) 2007-08-06 2009-04-23 Immunolight Methods and systems for treating cell proliferation disorders using two-photon simultaneous absorption
TWI458512B (zh) * 2008-02-21 2014-11-01 Immunolight Llc 利用電漿子增強之光譜療法（ｐｅｐｓｔ）及激子－電漿增強之光療法〈epep〉治療細胞增生病症之組合物及產生自體疫苗之系統
US8770203B2 (en) 2008-07-14 2014-07-08 Immunolight, Llc. Advanced methods and systems for treating cell proliferation disorders

Also Published As

Publication number Publication date
WO2009105662A9 (en) 2009-10-29
TW200946164A (en) 2009-11-16
US20170196977A1 (en) 2017-07-13
TWI574712B (zh) 2017-03-21
US8951561B2 (en) 2015-02-10
US20100003316A1 (en) 2010-01-07
AR070461A1 (es) 2010-04-07
US20160243235A1 (en) 2016-08-25
US9283275B2 (en) 2016-03-15
US20150265706A1 (en) 2015-09-24
US9662388B2 (en) 2017-05-30
TW201501741A (zh) 2015-01-16
TWI458512B (zh) 2014-11-01
WO2009105662A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
PT2040755E (pt) Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
BRPI0803374A2 (pt) compostos polihidróxi como agentes de extinção de polimerização
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
CL2011001497A1 (es) Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico.
CL2007002682A1 (es) Compuestos derivados de 4-metilpiridopirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el crecimiento anormal de celulas, como cancer.
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BR112013018352A2 (pt) composição de minociclina tópica e método
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
EA201290888A1 (ru) Фармацевтическая композиция, содержащая производное пиримидинона
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
AR072685A1 (es) Composicion topica para el tratamiento de queratosis actinica
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
TW200942530A (en) Pyridine compounds
CL2009000949A1 (es) Compuestos derivados de 1,2,3,5-tetrahidro-indolizina, 6,7,8,9-tetrahidro-4h-quinolizina sustituidos, inhibidores de la actividad de cinasa de mek; su composicion farmaceutica; su uso para el tratamiento de enfermedades hiperproliferativas, tal como cancer e inflamaciones.
AR075301A1 (es) Composicion y metodo para controlar enfermedades de plantas
BRPI0911573A2 (pt) preservativo com agente ativo localizado.